Zhou Z, Song X, Wu A, Liu H, Wu H, Wu Q, et al. Pulmonary emphysema is a risk factor for radiation pneumonitis in NSCLC patients with squamous cell carcinoma after thoracic radiation therapy. Sci Rep. 2017;7(1):2748.
Article PubMed PubMed Central Google Scholar
Li F, Zhou Z, Wu A, Cai Y, Wu H, Chen M, et al. Preexisting radiological interstitial lung abnormalities are a risk factor for severe radiation pneumonitis in patients with small-cell lung cancer after thoracic radiation therapy. Radiat Oncol. 2018;13(1):82.
Article PubMed PubMed Central Google Scholar
Roach M 3rd, Gandara DR, Yuo HS, Swift PS, Kroll S, Shrieve DC, et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol. 1995;13(10):2606–12.
Bradley JD, Hope A, El Naqa I, Apte A, Lindsay PE, Bosch W, et al. A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys. 2007;69(4):985–92.
Article PubMed PubMed Central Google Scholar
Hope AJ, Lindsay PE, El Naqa I, Alaly JR, Vicic M, Bradley JD, et al. Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys. 2006;65(1):112–24.
Valdes G, Solberg TD, Heskel M, Ungar L, Simone CB 2. Using machine learning to predict radiation pneumonitis in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy. Phys Med Biol. 2016;61(16):6105–20. nd. .
Article CAS PubMed PubMed Central Google Scholar
Yakar M, Etiz D, Metintas M, Ak G, Celik O. Prediction of Radiation Pneumonitis With Machine Learning in Stage III Lung Cancer: A Pilot Study. Technol Cancer Res Treat. 2021;20:15330338211016373.
Article CAS PubMed PubMed Central Google Scholar
Bourbonne V, Da-Ano R, Jaouen V, Lucia F, Dissaux G, Bert J, et al. Radiomics analysis of 3D dose distributions to predict toxicity of radiotherapy for lung cancer. Radiother Oncol. 2021;155:144–50.
Article CAS PubMed Google Scholar
Puttanawarut C, Sirirutbunkajorn N, Tawong N, Jiarpinitnun C, Khachonkham S, Pattaranutaporn P, et al. Radiomic and Dosiomic Features for the Prediction of Radiation Pneumonitis Across Esophageal Cancer and Lung Cancer. Front Oncol. 2022;12:768152.
Article PubMed PubMed Central Google Scholar
Lee G, Lee HY, Park H, Schiebler ML, van Beek EJR, Ohno Y, et al. Radiomics and its emerging role in lung cancer research, imaging biomarkers and clinical management: State of the art. Eur J Radiol. 2017;86:297–307.
Thawani R, McLane M, Beig N, Ghose S, Prasanna P, Velcheti V, et al. Radiomics and radiogenomics in lung cancer: A review for the clinician. Lung cancer (Amsterdam Netherlands). 2018;115:34–41.
Fried DV, Tucker SL, Zhou S, Liao Z, Mawlawi O, Ibbott G, et al. Prognostic value and reproducibility of pretreatment CT texture features in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;90(4):834–42.
Article PubMed PubMed Central Google Scholar
Sun W, Jiang M, Dang J, Chang P, Yin FF. Effect of machine learning methods on predicting NSCLC overall survival time based on Radiomics analysis. Radiation Oncol (London England). 2018;13(1):197.
Lu MT, Ivanov A, Mayrhofer T, Hosny A, Aerts H, Hoffmann U. Deep Learning to Assess Long-term Mortality From Chest Radiographs. JAMA Netw open. 2019;2(7):e197416.
Article PubMed PubMed Central Google Scholar
Duijm M, van der Voort van Zyp NC, Granton PV, van de Vaart P, Mast ME, Oomen-de Hoop E, et al. Prognostic factors of local control and disease free survival in centrally located non-small cell lung cancer treated with stereotactic body radiation therapy. Acta Oncol. 2020;59(7):809–17.
Kang J, Ning MS, Feng H, Li H, Bahig H, Brooks ED, et al. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms. Int J Radiat Oncol Biol Phys. 2020;106(1):90–9.
Article CAS PubMed Google Scholar
Qiu B, Xiong M, Luo Y, Li Q, Chen N, Chen L, et al. Hypofractionated Intensity Modulated Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer: A Phase II Prospective Clinical Trial (GASTO1011). Pract Radiat Oncol. 2021;11(5):374–83.
Kong FM, Ritter T, Quint DJ, Senan S, Gaspar LE, Komaki RU, et al. Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys. 2011;81(5):1442–57.
Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C, et al. LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer Res. 2018;78(16):4786–9.
Article CAS PubMed Google Scholar
Smola AJ, Scholkopf B. A tutorial on support vector regression. Stat Comput. 2004;14(3):199–222.
Wu MT, Chang JM, Chiang AA, Lu JY, Hsu HK, Hsu WH, et al. Use of quantitative CT to predict postoperative lung function in patients with lung cancer. Radiology. 1994;191(1):257–62.
Article CAS PubMed Google Scholar
Lafata KJ, Zhou Z, Liu JG, Hong J, Kelsey CR, Yin FF. An Exploratory Radiomics Approach to Quantifying Pulmonary Function in CT Images. Sci Rep. 2019;9(1):11509.
Article PubMed PubMed Central Google Scholar
Occhipinti M, Paoletti M, Bartholmai BJ, Rajagopalan S, Karwoski RA, Nardi C, et al. Spirometric assessment of emphysema presence and severity as measured by quantitative CT and CT-based radiomics in COPD. Respir Res. 2019;20(1):101.
Article PubMed PubMed Central Google Scholar
Ganeshan B, Panayiotou E, Burnand K, Dizdarevic S, Miles K. Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. Eur Radiol. 2012;22(4):796–802.
Bradley JD, Ieumwananonthachai N, Purdy JA, Wasserman TH, Lockett MA, Graham MV, et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2002;52(1):49–57.
Lopez Guerra JL, Gomez D, Zhuang Y, Levy LB, Eapen G, Liu H, et al. Change in diffusing capacity after radiation as an objective measure for grading radiation pneumonitis in patients treated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1573–9.
Park YH, Kim JS. Predictors of radiation pneumonitis and pulmonary function changes after concurrent chemoradiotherapy of non-small cell lung cancer. Radiation Oncol J. 2013;31(1):34–40.
Torre-Bouscoulet L, Muñoz-Montaño WR, Martínez-Briseño D, Lozano-Ruiz FJ, Fernández-Plata R, Beck-Magaña JA, et al. Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung Cancer. Respir Res. 2018;19(1):72.
Article CAS PubMed PubMed Central Google Scholar
Zhou Y, Yan T, Zhou X, Cao P, Luo C, Zhou L, et al. Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al]. 2020;196(6):505–14.
Dieterich LC, Bikfalvi A. The tumor organismal environment: Role in tumor development and cancer immunotherapy. Sem Cancer Biol. 2020;65:197–206.
Khorrami M, Prasanna P, Gupta A, Patil P, Velu PD, Thawani R, et al. Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer. Cancer Immunol Res. 2020;8(1):108–19.
Article CAS PubMed Google Scholar
Dehing-Oberije C, Yu S, De Ruysscher D, Meersschout S, Van Beek K, Lievens Y, et al. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;74(2):355–62.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919–29.
Article CAS PubMed Google Scholar
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342–50.
Article CAS PubMed Google Scholar
Peng L, Wu YL. Immunotherapy in the Asiatic population: any differences from Caucasian population? J Thorac disease. 2018;10(Suppl 13):1482-s93.
Zhao B, Tan Y, Tsai WY, Schwartz LH, Lu L. Exploring Variability in CT Characterization of Tumors: A Preliminary Phantom Study. Translational Oncol. 2014;7(1):88–93.
Lu EL, Li L, Yang L, Schwartz H, Zhao LH. B. Radiomics for Classification of Lung Cancer Histological Subtypes Based on Nonenhanced Computed Tomography. Acad Radiol. 2019;26(9):1245–52.
留言 (0)